凱普生物(300639.SZ):獲授予1項發明專利權
格隆匯6月17日丨凱普生物(300639.SZ)公佈,近日,公司、公司全資子公司潮州凱普生物化學有限公司(“凱普化學”)、廣州凱普醫藥科技有限公司(“凱普醫藥”)以及控股子公司北京凱普醫學檢驗實驗室有限公司(“北京凱普檢驗實驗室”)收到國家知識產權局下發的《授予發明專利權通知書》,發明創造名稱為種檢測α-地中海貧血的核酸組合物、其基因芯片、其試劑盒及其應用。
上述發明專利權的取得不會對公司目前的經營狀況產生重大的影響,但有利於進一步完善公司的知識產權體系,充分發揮公司的知識產權優勢,促進公司產品結構的不斷豐富,提升公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.